-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Zentek Receives Approval for Nasdaq Listing
Zentek Receives Approval for Nasdaq Listing
GUELPH, ON / ACCESSWIRE / March 7, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, today announces that it has received approval to have its common stock listed on the Nasdaq Capital Market ("Nasdaq") under the symbol ZTEK. Zentek's common stock will continue to trade on the TSX Venture Exchange (TSX-V) under the symbol ZEN. The Company is evaluating market conditions and other considerations and will announce the date its shares will commence trading in due course but no later than the 60-day limit as of March 4th.
Greg Fenton, CEO of Zentek, commented, "We believe the move to Nasdaq will be pivotal in generating additional interest and awareness in the U.S. investment community and is reflective of our transition to a global technology company focused on disruptive intellectual property in the areas of healthcare and sustainability. We anticipate this listing will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at .
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek Ltd.
View source version on accesswire.com:
GUELPH, ON / ACCESSWIRE / March 7, 2022 / Zentek Ltd. ("ZEN" or the "Company") (TSX-V:ZEN and OTC PINK:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions, today announces that it has received approval to have its common stock listed on the Nasdaq Capital Market ("Nasdaq") under the symbol ZTEK. Zentek's common stock will continue to trade on the TSX Venture Exchange (TSX-V) under the symbol ZEN. The Company is evaluating market conditions and other considerations and will announce the date its shares will commence trading in due course but no later than the 60-day limit as of March 4th.
Guelph,on/ACCESSWIRE/2022年3月7日/Zentek Ltd. ("禪宗“或”公司(多倫多證券交易所股票代碼:ZEN和OTC PINK:ZENYF),一家專注於下一代醫療解決方案的加拿大知識產權開發和商業化公司今天宣佈,它已經獲得批准,其普通股可以在納斯達克資本市場(以下簡稱納斯達克)上市,代碼為ZTEK。Zentek的普通股將繼續在多倫多證券交易所創業板交易,代碼為ZEN。該公司正在評估市場狀況和其他考慮因素,並將宣佈其股票開始交易的日期.
Greg Fenton, CEO of Zentek, commented, "We believe the move to Nasdaq will be pivotal in generating additional interest and awareness in the U.S. investment community and is reflective of our transition to a global technology company focused on disruptive intellectual property in the areas of healthcare and sustainability. We anticipate this listing will improve the visibility of our stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."
Zentek首席執行官格雷格·芬頓評論説:“我們相信,轉向納斯達克將對提高美國投資界的興趣和知名度起到關鍵作用,也反映了我們向一家專注於醫療保健和可持續發展領域顛覆性知識產權的全球科技公司的轉變。我們預計此次上市將提高我們股票的知名度,提高我們股票的交易流動性,併為我們提供更多接觸機構投資者的機會。”
About Zentek Ltd.
關於Zentek有限公司
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.
Zentek是一家知識產權開發和商業化公司,專注於預防、檢測和治療領域的下一代醫療解決方案。Zentek正在將禪宗商業化警衞™是一種正在申請專利的塗料,具有99%的抗菌活性,包括對新冠肺炎的抗菌活性,並有可能將類似化合物用作治療傳染病的藥品。該公司還簽訂了一項獨家協議,將成為一項新開發的、高度可擴展的、基於適體的快速病原體檢測技術的全球獨家商業化合作夥伴。
For further information:
有關更多信息,請訪問:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
馬特·布拉澤(Matt Blazei)
電話:(212)655-0924
電子郵件:mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at .
欲瞭解更多有關Zentek Ltd.的信息,請訪問我們的網站:。本新聞稿的副本和與本公司有關的所有重要文件可在Zen的SEDAR簡介中獲得,網址為。
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
本新聞稿包含前瞻性陳述。由於前瞻性陳述涉及未來的事件和條件,因此它們本身就包含固有的風險和不確定因素。儘管Zentek認為在準備本新聞稿中的前瞻性信息時使用的假設和因素是合理的,但不應過度依賴這些信息,因為這些信息只適用於本新聞稿發佈之日,不能保證此類事件將在披露的時間框架內發生或根本不會發生。除法律要求外,Zentek沒有任何更新或修改任何前瞻性信息的意圖或義務,無論是由於新信息、未來事件還是其他原因。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
SOURCE: Zentek Ltd.
資料來源:Zentek Ltd.
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧